Lipocine (LPCN) Other financing activities (2013 - 2022)

Lipocine's (LPCN) quarterly Other financing activities came in at $5344.0 in Q3 2022, up 5772.53% on a QoQ basis from $91.0 in Q2 2022.

Lipocine (LPCN) Other financing activities (2013 - 2022) Analysis & Trends

Lipocine (LPCN) has 9 years of Other financing activities data on file, last reported at $5344.0 in Q3 2022.

Quarterly Other financing activities changed N/A year-over-year to $5344.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $211423.0 (up 3058.87% YoY) and the FY2022 annual result came in at $211423.0, up 3058.87% from the prior year.
Other financing activities improved to $5344.0 in Q3 2022, from $91.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $6.9 million in Q2 2020 to a low of -$25124.0 in Q4 2020.
A 4-year average of $885632.4 and a median of $56200.0 in 2019 frame the typical range for Other financing activities.
Annual changes were most pronounced in 2021 — Other financing activities tumbled 88.94% — and 2022, when it surged 2977.66%.
Tracing LPCN's Other financing activities over 4 years: stood at $56200.0 in 2019, then sank by 144.7% to -$25124.0 in 2020, then jumped by 126.64% to $6693.0 in 2021, then declined by 20.16% to $5344.0 in 2022.
The last three Other financing activities figures came in at $5344.0 (Q3 2022), $91.0 (Q2 2022), and $205988.0 (Q1 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lipocine	11.15 Mn	-12.76 Mn	-

Download Data